This CPB has been revised to state that Jivi [antihemophilic factor (recombinant), PEGylated-aucl] is considered medically necessary in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.